Effect of Pravastatin (10 mg/day) on Progression of Coronary Atherosclerosis in Patients With Serum Total Cholesterol Levels from 160 to 220 mg/dl and Angiographically Documented Coronary Artery Disease

Three-Year Follow-up Results of Angiographic Intervention Trial Using an HMG-CoA Reductase Inhibitor to Evaluate Retardation of Obstructive Multiple Atheroma (ATHEROMA) Study

“…Very few papers evaluating the effect of statins on coronary atherosclerosis by angiographic assessment in Japanese patients have been published. [27][28][29] Although previous epidemiological studies have indicated that the incidence of CAD is much lower in Asians compared with Caucasians, 1,2 it is unclear whether this difference is a result of variations in the progression of coronary atherosclerosis or because of the good response to statin treatment in Japanese and Western patients. Thus, the purpose of the study was to clarify how statin therapy, specifically pravastatin, benefits CAD patients with slightly to moderately elevated cholesterol concentrations.…”

“…Both the MEGA study and the current study organized by the Japanese Ministry of Health and Welfare, were started at the same time using a similar supervising system. Only a few angiographic studies [27][28][29] have been conducted in Japan, although these studies have tended to be lacking in scientific method and objectivity, eg, non-quantitative data, non-computerized QCA and a small sample size, etc.…”

Statins and total (not LDL) cholesterol concentration and outcome of myocardial infarction: results from a meta-analysis and an observational study

“…In the 14 secondary prevention studies, patients were randomised to statin treatment or placebo: pravastatin (7 trials and 15,769 participants) [5,8,[15][16][17][18][19], simvastatin (3 trials and 5,825 participants) [20][21][22], lovastatin (2 trials and 601 participants) [23,24], and fluvastatin (2 trials and 794 participants) [25,26]. The lipid concentrations in both groups were measured and reported in all trials at baseline and the end of follow-up.…”

Effect of Conventional Dose of Simvastatin on Plaque Regression and Vascular Remodeling in the Peristent Reference Segments of Normocholesterolemic Patients: A Serial Intravascular Ultrasound Assessment

“…Nakagawa et al 23) reported that cholesterol-lowering pravastatin therapy prevents the progression of coronary atherosclerosis in normocholesterolemic patients with coronary artery disease. Tamura et al 24) reported that this therapy could prevent the progression of coronary atherosclerosis even in normocholesterolemic patients with an established coronary artery disease.…”